Rafferty Asset Management LLC Makes New $436,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Rafferty Asset Management LLC bought a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 252,257 shares of the company's stock, valued at approximately $436,000. Rafferty Asset Management LLC owned approximately 0.12% of Taysha Gene Therapies at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its position in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after acquiring an additional 11,390 shares during the last quarter. LPL Financial LLC bought a new stake in Taysha Gene Therapies in the fourth quarter valued at $104,000. Adage Capital Partners GP L.L.C. bought a new position in Taysha Gene Therapies during the 4th quarter valued at about $8,650,000. Hsbc Holdings PLC grew its position in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after acquiring an additional 8,076 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Taysha Gene Therapies by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after purchasing an additional 641,305 shares in the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on TSHA shares. Canaccord Genuity Group boosted their target price on Taysha Gene Therapies from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Friday, May 16th. Chardan Capital reiterated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Finally, JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Monday, April 28th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $6.57.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock traded down $0.04 during mid-day trading on Wednesday, reaching $2.58. The company had a trading volume of 498,120 shares, compared to its average volume of 2,900,012. The business has a fifty day simple moving average of $1.87 and a 200 day simple moving average of $1.89. The company has a market cap of $552.75 million, a P/E ratio of 4.10 and a beta of 0.90. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The firm had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same period last year, the firm posted ($0.10) earnings per share. On average, equities research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.